The TreEat Study- Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants With Peanut Allergy

Sponsor
Murdoch Childrens Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04801823
Collaborator
(none)
200
1
2
35
5.7

Study Details

Study Description

Brief Summary

Early and regular ingestion of the common allergens, peanut and egg has been shown to be an effective allergy prevention strategy. It is not clear whether this is also true of tree nut allergy. Current practice in many Australian allergy clinics for children with peanut allergy (high risk of tree nut allergy), is to advise families to introduce each individual tree nut into their child's diet via a cautious home introduction protocol without prior allergy testing (screening). The safety and effectiveness of an early and regular ingestion strategy for the prevention of tree nut allergy has not been formally evaluated and it is known that around a third of children with peanut allergy develop one or more other nut allergies. This trial is a 2-armed, open-label, randomized, controlled trial (RCT) to assess the safety and efficacy of a supervised hospital based multi-tree nut (almond, cashew, hazelnut and walnut) oral food challenge (OFC) + then home introduction of the remaining tree nuts versus standard care (home introduction of all 8 tree nuts) in infants with peanut allergy to reduce the risk of developing tree nut allergy.

Condition or Disease Intervention/Treatment Phase
  • Other: Home introduction
  • Other: Multi Nut oral food challenge
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants at High Risk of Tree Nut Allergy: The TreEat Study: a Randomised, Open-label Controlled Trial
Actual Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Home Introduction of Individual tree nuts

Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.

Other: Home introduction
Cautious, graded introduction of individual tree nuts

Experimental: In hospital multi-tree nut (almond, cashew hazelnut and walnut) oral food challenge (OFC)

Infant will be booked for a 4-nut butter (Almond, Hazelnut, Walnut, and Cashew) graded and supervised OFC in the allergy clinical trials unit at the Murdoch Children's Research Institute. The nut butter contains a 1g dose of each nut protein in a total weight of 20g. Doses will be administered every 15minutes (1. Smear to inside of lip, 2.1/8 teaspoon, 3.1/4 teaspoon, 4.1/2 teaspoon, 5.1 teaspoon, 6.remainder of 20g nut butter paste) If challenge negative, infants continue home introduction of tree nuts as per written instructions provided. If challenge positive, infants will have additional SPT (for full tree nut panel) and single tree nut OFC as per protocol to determine tolerance/allergic status (and +/- home introduction recommendation) for each tree nut.

Other: Multi Nut oral food challenge
In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)

Outcome Measures

Primary Outcome Measures

  1. Difference between the two treatment arms in the proportion of participants with clinical confirmed tree nut allergy at 18 months of age [18 months of age]

    Tree nut allergy outcomes at 18 months will be defined as: Allergic - has evidence of tree nut sensitization (SPT>=3mm) and has had a reaction consistent with IgE (immunoglobulin E) mediated food allergy OR positive formal OFC Tree nut tolerant- successfully tolerated the tree nut at home on more than 3 occasions of at least 1 teaspoon of nut per occasion OR has had a negative formal OFC. Inconclusive -has an unknown outcome as ingestion has not occurred and participant declines OFC.

Secondary Outcome Measures

  1. Difference between the two treatment arms in the proportion of participants with ongoing peanut allergy at 18 months of age [18 months of age]

    Peanut allergy will be defined as peanut sensitization (SPT >=3mm) AND has had a reaction consistent with IgE mediated food allergy since randomization OR positive formal OFC

  2. Difference between the two treatment arms in the proportion and severity of reported adverse events (AE) related to tree nut ingestion. [18 months of age]

    Number and severity of adverse events (AE) as assessed by standardised predetermined criteria, related to tree nut ingestion from randomization to 18 months of age collected via parent questionnaire and medical history.

  3. Difference between the two treatment arms in the proportion and severity of solicited AEs related to tree nut ingestion. [18 months of age]

    Number and severity of solicited AEs as assessed by standardized predetermined criteria, related to tree nut ingestion from randomization to 18 months of age collected via parent questionnaire and medical history.

  4. Difference between the 2 treatment arms in the number of tree nuts ingested. [18 months of age]

    Parent reported tree nut ingestion history based on questionnaire at baseline and 18 months of age. 0-8 tree nuts and the higher the number of tree nuts the better.

  5. Difference between the 2 treatment arms in the frequency of tree nuts ingested. [18 months of age]

    Parent reported tree nut ingestion history based on questionnaire at baseline and 18 months of age. Range will be never to daily with higher frequency better.

  6. Difference between the two treatment arms in mean change from baseline of Quality of Life Scores using the Food Allergy Quality of Life Questionnaire (FAQLQ-PF)- Parent Form at 18 months of age. [Baseline and 18 months of age]

    The Food Allergy Quality of Life Questionnaires (FAQLQ) are disease-specific health-related quality of life (HRQL) questionnaires for patients with food allergy. FAQLQ-PF (Parent Form), completed by parents of children aged 0-12 years consists of 30 items over 3 domains (emotional impact, food anxiety, social and dietary restrictions). Total and domain scores are calculated by dividing the sum of completed items by the number of completed items. Questions are based on a 6 point Likert scale with higher scores indicating greater impact on quality of life

  7. Difference between the two treatment arms in the mean change from baseline in State/Trait anxiety scores using the State/Trait Anxiety Inventory [Baseline and 18 months of age]

    The State-Trait Anxiety Inventory (STAI) is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis. The STAI measures two types of anxiety - state anxiety, or anxiety about an event, and trait anxiety, or anxiety level as a personal characteristic. The total score ranges from 0-63 with higher scores positively correlated with higher levels of anxiety.

  8. Difference in the number of allergy-related healthcare visits from randomization to 18 months of age between the treatment arms [18 months of age]

    Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions from randomization to 18 months of age.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Months to 11 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Infants aged greater than 4 months and less than 11 months of age diagnosed with IgE-mediated peanut allergy in conjunction with a positive SPT (≥3mm) or sIgE (specific immunoglobulin E) (>0.35 kU/L)

Exclusion Criteria:
  • Any history of severe food induced anaphylaxis. Defined as reaction requiring 2 doses of intramuscular (IM) adrenaline.

  • Pre-existing tree nut allergy (parent-reported).

  • Any tree nut already tolerated (ingestion on >3 occasions without reaction of around 1 teaspoon)

  • SPT or sIgE performed to any tree nuts

  • Not commenced or unable to eat solid food

  • Prescribed beta-blocker medication

Contacts and Locations

Locations

Site City State Country Postal Code
1 Murdoch Children's Research Institute (MCRI) Melbourne Victoria Australia 3052

Sponsors and Collaborators

  • Murdoch Childrens Research Institute

Investigators

  • Principal Investigator: Kirsten Perrett, MD. PhD, Murdoch Children's Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Murdoch Childrens Research Institute
ClinicalTrials.gov Identifier:
NCT04801823
Other Study ID Numbers:
  • 70489
First Posted:
Mar 17, 2021
Last Update Posted:
Sep 17, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Murdoch Childrens Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 17, 2021